Seeing Is Believing
Currently out of the existing stock ratings of Christopher Marai, 125 are a BUY (83.89%), 9 are a HOLD (6.04%), 15 are a SELL (10.07%).
Analyst Christopher Marai works with a stock forecast success ratio of 57.94% fulfilled within 383.92 days on average. Previously, Christopher Marai worked at NOMURA, OPPENHEIMER.
Christopher Marai’s has documented 293 price targets and ratings displayed on 24 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on CRBP, Corbus Pharmaceuticals at 04-Jun-2020.
Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 6/20/2016. The price target of $60 was fulfilled within 94 days with a profit of $42.15 (236.13%) receiving and performance score of 25.12.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
234
$79.61 (51.56%)
234
1 days ago
0/3 (0%)
$79.61 (51.56%)
Buy
235
$80.61 (52.21%)
235
1 months 8 days ago
2/14 (14.29%)
$85.31 (56.99%)
149
Buy
227
$72.61 (47.03%)
237
1 months 12 days ago
14/22 (63.64%)
$80 (54.42%)
171
Hold
161
$6.61 (4.28%)
171
1 months 12 days ago
2/2 (100%)
$14 (9.52%)
5
Buy
225
$70.61 (45.73%)
250
1 months 12 days ago
2/6 (33.33%)
$78 (53.06%)
435
What Year was the first public recommendation made by Christopher Marai?